| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3382725 | Reumatología Clínica | 2016 | 4 Pages |
Abstract
Although uncommon, during TNF antagonist therapy, TB risk persists despite negative initial screening, so clinicians should be aware of TB during the entire treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
José Antonio Bernal, Mariano Andrés, Vega JovanÃ, Raquel GarcÃa Sevila, Alejandra Begazo, Paloma Vela,